4sc-101

Zotiraciclib, also known as TG02 and SB1317, is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, with 80 percent of glioblastomas characterized by this property.

Vidofludimus (SC12267) 是一种新型的二氢乳清酸脱氢酶 (DHODH) 小分子抑制剂，可在不影响淋巴细胞增殖的条件下抑制IL-17的分泌。

Vidofludimus (4sc-101 ; SC12267) hemicalcium 是一种口服有效的二氢乳清酸脱氢酶 (DHODH) 的抑制剂，也是法尼醇 X 受体 (FXR) 调节剂。Vidofludimus hemicalcium 作为一种免疫调节剂，可用于研究自身免疫性疾病，如炎症性肠病 (IBD)。Vidofludimus hemicalcium 还可通过靶向FXR 用于脂肪肝的研究。